Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

An international collaboration between the University of Oxford and other European institutions has uncovered a correlation between a rare mutation in bowel cancers and a better prognosis, raising the possibility that patients with such tumours may not require chemotherapy after surgery. Dr David Church was joint senior author of the study.